TY - JOUR T1 - Metabolism and Pharmacokinetics, in the Rat, of (<em>R</em>)-<em>N</em>-(2-Heptyl)Methyl-Propargylamine (<em>R</em>-2HMP), A New Potent Monoamine Oxidase Inhibitor and Antiapoptotic Agent JF - Drug Metabolism and Disposition JO - Drug Metab Dispos SP - 147 LP - 154 VL - 28 IS - 2 AU - David A. Durden AU - Lillian E. Dyck AU - Bruce A. Davis AU - Ya-Dong Liu AU - Alan A. Boulton Y1 - 2000/02/01 UR - http://dmd.aspetjournals.org/content/28/2/147.abstract N2 - (R)-N-(2-Heptyl)-N-methylpropargylamine (R-2HMP) is a monoamine oxidase inhibitor and putative antiapoptotic agent analogous to (R)-deprenyl. In the rat, the major amine metabolites of R-2HMP have been identified as (R)-N-2-heptylmethylamine (R-2HMA), (R)-N-2-heptylpropargylamine (R-2HPA), and (R)-2-heptylamine (R-2HA). After R-2HMP was administered s.c. to male Wistar rats, it was observed that the greatest concentration was of the original drug followed in decreasing order byR-2HMA, R-2HPA, and R-2HA in brain, liver, and plasma at all times after administration. The greatest concentrations of the three metabolites were found in brain followed by liver and plasma, and the peak concentrations occurred between 15 and 30 min after administration. After oral administration, the liver contained the greatest concentrations of drug and metabolites, and, again, the peak concentrations occurred at about 15 min. In all cases, depropargylation appears to occur at a faster rate than demethylation. After s.c. administration, R-2HMP and its metabolites exhibited biexponential redistribution and elimination losses. Half-lives of the compounds in brain for the redistribution phase were: R-2HMP, 10 min;R-2HMA, 11 min; R-2HPA, 16 min; andR-2HA, 15 min. The American Society for Pharmacology and Experimental Therapeutics ER -